media – Page 576 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

China’s Import and Export Report of External Use Otology Drugs

According to the latest statistics of World Health Organization (WHO), the number of people with hearing disabilities in the world has reached 360 million. With the ageing population and the number of hearing-impaired persons increasing year by year, the external otology drugs market shows an increasing trend.
- Source: Ddu
- 41,317
- January 12, 2018
Ddu College otology drugs
NHS Confed orders reports into NHS funding needs

The NHS Confederation has tasked the Institute for Fiscal Studies and the Health Foundation with analysing the funding needs of the UK’s health and care systems over the next 15 years.
- Source: pharmatimes
- 508
- January 12, 2018
health NHS polices
Depression medication initiation may lower oral antidiabetic drug adherence in diabetes

Adults with type 2 diabetes and major depressive disorders who begin using second-generation antipsychotics are more likely to have at least a 10% decline in oral antidiabetic drug use 180 to 365 days after initiation compared with nonusers of second-generation antipsychotics, according to a study.
- Source: Healio
- 633
- January 12, 2018
antipsychotics diabetes Researches
Sex hormone-binding globulin associated with androgen deficiency

Higher levels of sex hormone-binding globulin were associated with androgen deficiency in men, independent of total testosterone level, researchers in Italy reported.
- Source: healio
- 423
- January 12, 2018
androgen deficiency Researches sex hormone
Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies

Celgene Corporation (CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible.
- Source: finance.yahoo
- 510
- January 12, 2018
Celgene FDA Fedratinib Impact Market Views myelofibrosis
Alzheimer’s Drug Turns Back Clock in Powerhouse of Cell

The experimental drug J147 is something of a modern elixir of life; it’s been shown to treat Alzheimer’s disease and reverse aging in mice and is almost ready for clinical trials in humans.
- Source: Neuroscience News
- 593
- January 12, 2018
Alzheimer's disease Clinical Trials Researches
GE Healthcare and Roche join forces to create clinical decision support tools

GE Healthcare and Roche have launched a partnership to assist clinicians in making better choices and help patients get individualized care.
- Source: MedCityNews
- 577
- January 12, 2018
Clinical Company Insight Roche
New AI technology significantly improves human kidney analysis

The ability to quantify the extent of kidney damage and predict the life remaining in the kidney, using an image obtained at the time when a patient visits the hospital for a kidney biopsy, now is possible using a computer model based on artificial intelligence (AI).
- Source: Medical Xpress
- 637
- January 12, 2018
AI kidney Researches
Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab)

Eisai Co., Ltd. and Merck (MRK), known as MSD outside the United States and Canada, announced that they received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Eisai's multiple receptor tyrosine kinase inhibitor LENVIMA® (lenvatinib) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the potential treatment of patients with advanced and/or metastatic renal cell carcinoma (RCC).
- Source: finance.yahoo
- 534
- January 11, 2018
LENVIMA New Approvals RCC
FDA Accepts New Drug Applications for Merck’s Doravirine

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two New Drug Applications (NDAs) for doravirine, the company’s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection in adults.
- Source: investors.merck
- 512
- January 11, 2018
doravirine NDAs New Approvals NNRTI

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.